Articles

Sequence Listing Requirements for Diagnostic and Biomarker Patents

If you are filing a patent related to diagnostics or biomarkers, understanding the concept of a diagnostic patent sequence listing is not optional. It is a core part of your patent application. A sequence listing is a standardized, machine-readable document that describes the biological sequences, such as DNA, RNA, or protein sequences, that are claimed or disclosed in your patent. Without a properly formatted sequence listing, your application can face delays, objections, or even rejection.

Diagnostic patents are unique. They often rely on specific nucleotide probes, primer sequences, or protein biomarkers that identify diseases, genetic conditions, or biological states. Every one of those sequences must be disclosed correctly. Patent offices around the world, including the USPTO, EPO, and WIPO, have strict rules on how this must be done. Getting it right from the beginning saves time, money, and protects your invention fully.

Understanding the Legal Framework: WIPO ST.26 and Its Impact

The biggest change in recent years for diagnostic patent sequence listing compliance came with the adoption of WIPO Standard ST.26. This replaced the older ST.25 standard in July 2022. Every patent applicant dealing with biological sequences must now comply with ST.26, regardless of which country they are filing in.

Here is what ST.26 changed and why it matters specifically for diagnostic and biomarker patents:

XML-based format: ST.26 requires sequence listings to be submitted as XML files, replacing the plain-text format of ST.25. This makes data more structured and machine-readable.
Broader sequence coverage: ST.26 now includes linear and branched sequences, D-amino acids, and modified nucleotides, which are increasingly common in modern diagnostic assays and biomarker research.
Single standard for all offices: A single ST.26-compliant sequence listing can be used across multiple patent offices, simplifying international filings under the PCT (Patent Cooperation Treaty).
No nucleotide threshold: Unlike ST.25, which required listing only sequences of 10 or more nucleotides, ST.26 has slightly different thresholds and qualification rules that applicants must carefully verify.

For biomarker patent applicants, this is particularly important because many biomarker sequences are short, highly specific, and modified. Understanding whether your sequence qualifies for listing under ST.26 rules is a critical first step.

Which Sequences Must Be Listed in a Diagnostic or Biomarker Patent?

Not every biological reference in your patent requires a formal sequence listing entry. However, the rules are specific, and mistakes in this area are extremely common. A proper diagnostic patent sequence listing must include sequences that meet the following criteria as defined by WIPO ST.26 and individual patent office rules.

Sequences that must be listed include:

Nucleotide sequences with 10 or more bases (with some exceptions for specific modified forms)
Amino acid sequences with 4 or more amino acids that have biological activity
Primer and probe sequences used in diagnostic assays (PCR primers, hybridization probes)
Sequences that form part of the claimed invention, even if they appear only in the description
Biomarker sequences used to identify a disease state, patient population, or biological condition

Sequences that are generally excluded:

Sequences described only by function without a disclosed structure
Sequences that are well-known and only referenced by name without novel context
Random or hypothetical sequences not tied to a specific biological entity

Getting this distinction right is where many applicants, especially first-time filers in the diagnostic space, make errors. A qualified sequence listing specialist or patent practitioner familiar with diagnostic patent sequence listing requirements can be invaluable at this stage.

Common Challenges in Diagnostic and Biomarker Sequence Listing Filings

Biomarker and diagnostic patent applications come with a unique set of challenges when preparing sequence listings. These are not just technical hurdles. They have legal and commercial consequences.

Challenge 1: Modified and Non-Standard Sequences

Many modern diagnostic tests use chemically modified oligonucleotides. Locked nucleic acids (LNAs), phosphorothioate backbones, and PNA probes are examples. Under ST.26, these modifications must be annotated correctly using specific feature keys and qualifiers. Incorrect annotation can lead to office actions or, worse, incomplete disclosure that weakens patent protection.

Challenge 2: Multi-sequence Claims

Diagnostic patents often claim families of sequences, such as a group of SNP variants or a panel of biomarker proteins. Each individual sequence in that family typically needs its own SEQ ID NO entry in the listing. Managing large panels efficiently, without missing any sequence or creating inconsistencies between the listing and the claims, requires careful coordination.

Challenge 3: Coordination Between Sequences and Claims

Every SEQ ID NO cited in the claims or description must correspond to a correctly numbered, accurately described entry in the sequence listing. Mismatches between what is claimed and what is listed can create serious prosecution issues and may require costly corrections later.

Best Practices for Preparing a Compliant Diagnostic Patent Sequence Listing

Following best practices from the beginning can prevent most of the common errors seen in diagnostic and biomarker patent filings. Here is what experienced practitioners recommend:

Start the sequence listing preparation early, ideally alongside the drafting of claims and the detailed description.
Use WIPO-approved ST.26 authoring tools such as WIPO Sequence to build and validate your XML file before submission.
Assign SEQ ID NOs sequentially and consistently throughout the entire application document.
Double-check all modified residues and non-standard bases against the ST.26 feature table to ensure correct annotation.
Validate the final XML file using the patent office’s own validation tools before filing.
Work with a professional experienced in diagnostic patent sequence listing preparation if your application involves complex or large sequence sets.

Filing a Diagnostic Patent Internationally: PCT and Sequence Listing Requirements

When filing internationally under the PCT, the same sequence listing submitted in the international phase should cover all designated offices. Thanks to ST.26, the standardized XML format is accepted globally. However, some national offices may have additional requirements during the national phase, such as translation requirements for free text qualifiers or additional formal checks.

For biomarker patents targeting markets in the US, Europe, and Asia simultaneously, it is wise to review the national phase requirements for each key jurisdiction early. This prevents having to amend or re-submit the diagnostic patent sequence listing separately in each country, which adds cost and delays.

Final Thoughts: Compliance Is Protection

A well-prepared diagnostic patent sequence listing is not just a regulatory formality. It is a direct reflection of the strength and completeness of your patent disclosure. In the highly competitive world of diagnostic and biomarker innovation, where patents define commercial exclusivity and licensing value, a flawed sequence listing can undermine years of research and development investment.

Whether you are a startup developing a novel liquid biopsy test, a research institution patenting a new genetic marker, or a large diagnostics company managing a global IP portfolio, the rules are the same. Understand the ST.26 standard, identify your sequences correctly, annotate them accurately, and validate thoroughly before filing. That is how you turn scientific discovery into protected intellectual property.

For professional assistance with your diagnostic patent sequence listing needs, visit The Sequence Listing and connect with experienced specialists today.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.